Brand Name :
sotyktu
Synonyms :
deucravacitinib
Class :
Dermatologics, tyrosine kinase inhibitors
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may decrease the therapeutic effect of COVID-19
may increase the immunosuppressive effects of corticosteroids
may decrease the therapeutic effect of influenza virus vaccine
may decrease the therapeutic effect of rabies vaccine
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the adverse effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the therapeutic effect of immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
may increase the immunosuppressive effects
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
may increase the immunosuppressive effect of Immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
Frequency defined:
>10%
Upper respiratory tract infections
Infections
1-10%
Herpes simplex
Folliculitis
Increased levels of blood creatinine phosphokinase
Mouth ulcers
Acne
<1%
Herpes zoster
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: deucravacitinib
Pronounced: (due krav a sye ti nib)
Why do we use deucravacitinib?
It is used in the treatment of psoriasis
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
